Literature DB >> 20406984

Receptor tyrosine kinase coactivation networks in cancer.

Alexander M Xu1, Paul H Huang.   

Abstract

Cancer cells employ multiple mechanisms to evade tightly regulated cellular processes such as proliferation, apoptosis, and senescence. Systems-wide analyses of tumors have recently identified receptor tyrosine kinase (RTK) coactivation as an important mechanism by which cancer cells achieve chemoresistance. This mini-review discusses our current understanding of the complex and dynamic process of RTK coactivation. We highlight how systems biology and computational modeling have been employed to predict integrated signaling outcomes and cancer phenotypes downstream of RTK coactivation. We conclude by providing an outlook on the feasibility of targeting RTK networks to overcome chemoresistance in cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406984      PMCID: PMC2875162          DOI: 10.1158/0008-5472.CAN-10-0163

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  A biological approach to computational models of proteomic networks.

Authors:  Kevin A Janes; Douglas A Lauffenburger
Journal:  Curr Opin Chem Biol       Date:  2006-01-06       Impact factor: 8.822

2.  Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

Authors:  Birgit Schoeberl; Emily A Pace; Jonathan B Fitzgerald; Brian D Harms; Lihui Xu; Lin Nie; Bryan Linggi; Ashish Kalra; Violette Paragas; Raghida Bukhalid; Viara Grantcharova; Neeraj Kohli; Kip A West; Magdalena Leszczyniecka; Michael J Feldhaus; Arthur J Kudla; Ulrik B Nielsen
Journal:  Sci Signal       Date:  2009-06-30       Impact factor: 8.192

3.  Transphosphorylation as a possible mechanism for insulin and epidermal growth factor receptor activation.

Authors:  R Lammers; E Van Obberghen; R Ballotti; J Schlessinger; A Ullrich
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

4.  Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.

Authors:  Natsumi Yamamoto; Gunay Mammadova; Robert X-D Song; Yasuo Fukami; Ken-ichi Sato
Journal:  J Cell Sci       Date:  2006-10-24       Impact factor: 5.285

5.  Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

Authors:  Li Liu; James Greger; Hong Shi; Yuan Liu; Joel Greshock; Roland Annan; Wendy Halsey; Ganesh M Sathe; Anne-Marie Martin; Tona M Gilmer
Journal:  Cancer Res       Date:  2009-08-11       Impact factor: 12.701

6.  Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.

Authors:  Paul H Huang; Akitake Mukasa; Rudy Bonavia; Ryan A Flynn; Zachary E Brewer; Webster K Cavenee; Frank B Furnari; Forest M White
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-23       Impact factor: 11.205

7.  Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.

Authors:  Xiaoping Huang; Lizhi Gao; Shuiliang Wang; James L McManaman; Ann D Thor; Xiaohe Yang; Francisco J Esteva; Bolin Liu
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701

8.  Effects of HER2 overexpression on cell signaling networks governing proliferation and migration.

Authors:  Alejandro Wolf-Yadlin; Neil Kumar; Yi Zhang; Sampsa Hautaniemi; Muhammad Zaman; Hyung-Do Kim; Viara Grantcharova; Douglas A Lauffenburger; Forest M White
Journal:  Mol Syst Biol       Date:  2006-10-03       Impact factor: 11.429

9.  Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility.

Authors:  Silvia Giampieri; Cerys Manning; Steven Hooper; Louise Jones; Caroline S Hill; Erik Sahai
Journal:  Nat Cell Biol       Date:  2009-10-18       Impact factor: 28.824

10.  Systems analysis of EGF receptor signaling dynamics with microwestern arrays.

Authors:  Mark F Ciaccio; Joel P Wagner; Chih-Pin Chuu; Douglas A Lauffenburger; Richard B Jones
Journal:  Nat Methods       Date:  2010-01-24       Impact factor: 28.547

View more
  79 in total

1.  Global molecular dysfunctions in gastric cancer revealed by an integrated analysis of the phosphoproteome and transcriptome.

Authors:  Tiannan Guo; Sze Sing Lee; Wai Har Ng; Yi Zhu; Chee Sian Gan; Jiang Zhu; Haixia Wang; Shiang Huang; Siu Kwan Sze; Oi Lian Kon
Journal:  Cell Mol Life Sci       Date:  2010-10-16       Impact factor: 9.261

2.  Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma.

Authors:  Y Gui; M Yeganeh; Y-C Donates; W-S Tobelaim; W Chababi; M Mayhue; A Yoshimura; S Ramanathan; C Saucier; S Ilangumaran
Journal:  Oncogene       Date:  2015-03-02       Impact factor: 9.867

3.  MYO1D binds with kinase domain of the EGFR family to anchor them to plasma membrane before their activation and contributes carcinogenesis.

Authors:  Yoo-Seung Ko; Jeong A Bae; Keon Young Kim; Sung Jin Kim; Eun Gene Sun; Kyung Hwa Lee; Nacksung Kim; Hyuno Kang; Young-Woo Seo; Hangun Kim; Ik Joo Chung; Kyung Keun Kim
Journal:  Oncogene       Date:  2019-08-16       Impact factor: 9.867

4.  Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.

Authors:  Aleksandra Bielen; Lara Perryman; Gary M Box; Melanie Valenti; Alexis de Haven Brandon; Vanessa Martins; Alexa Jury; Sergey Popov; Sharon Gowan; Sebastien Jeay; Florence I Raynaud; Francesco Hofmann; Darren Hargrave; Suzanne A Eccles; Chris Jones
Journal:  Mol Cancer Ther       Date:  2011-06-09       Impact factor: 6.261

Review 5.  Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer.

Authors:  Simon Vyse; Annie Howitt; Paul H Huang
Journal:  J Mol Biol       Date:  2017-05-03       Impact factor: 5.469

6.  Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.

Authors:  Marianne E Marshall; Trista K Hinz; Scott A Kono; Katherine R Singleton; Brady Bichon; Kathryn E Ware; Lindsay Marek; Barbara A Frederick; David Raben; Lynn E Heasley
Journal:  Clin Cancer Res       Date:  2011-06-14       Impact factor: 12.531

Review 7.  Discoidin domain receptors: a proteomic portrait.

Authors:  Leo K Iwai; Maciej T Luczynski; Paul H Huang
Journal:  Cell Mol Life Sci       Date:  2014-04-05       Impact factor: 9.261

8.  Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.

Authors:  Kathryn E Ware; Marianne E Marshall; Lydia R Heasley; Lindsay Marek; Trista K Hinz; Paula Hercule; Barbara A Helfrich; Robert C Doebele; Lynn E Heasley
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

9.  Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.

Authors:  Lindsay A Marek; Trista K Hinz; Anne von Mässenhausen; Kyle A Olszewski; Emily K Kleczko; Diana Boehm; Mary C Weiser-Evans; Raphael A Nemenoff; Hans Hoffmann; Arne Warth; Joseph M Gozgit; Sven Perner; Lynn E Heasley
Journal:  Mol Cancer Res       Date:  2014-06-25       Impact factor: 5.852

Review 10.  Exploiting receptor tyrosine kinase co-activation for cancer therapy.

Authors:  Aik-Choon Tan; Simon Vyse; Paul H Huang
Journal:  Drug Discov Today       Date:  2016-07-21       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.